Elicio Therapeutics, Inc. (ELTX)
(Delayed Data from NSDQ)
$4.85 USD
-0.05 (-1.02%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $4.78 -0.07 (-1.44%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Elicio Therapeutics (ELTX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$10.00 | $10.00 | $10.00 | 104.08% |
Price Target
Only one analyst offered a short-term price target of $10.00 for Elicio Therapeutics. This represents an increase of 104.08% from the last closing price of $4.90.
Analyst Price Targets (1 )
Broker Rating
Elicio Therapeutics currently has an average brokerage recommendation (ABR) of 2.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by two brokerage firms. The current ABR compares to an ABR of 2.00 a month ago based on two recommendations.
Of the two recommendations deriving the current ABR, one is Strong Buy, representing 50% of all recommendations. A month ago, Strong Buy represented 50%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 1 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/16/2024 | Not Identified | Not Identified | Hold | Hold |
5/1/2024 | H.C. Wainwright & Co. | Robert Burns | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.00 |
ABR (Last week) | 2.00 |
# of Recs in ABR | 2 |
Average Target Price | $10.00 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 81 of 252 |
Current Quarter EPS Est: | -0.96 |